<DOC>
	<DOCNO>NCT01646567</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability clinical activity SHP-141C topical cream formulation patient plaque type psoriasis .</brief_summary>
	<brief_title>SHP-141C Plaque Type Psoriasis</brief_title>
	<detailed_description>Psoriasis chronic , relapse immunoinflammatory disorder . Chronic plaque psoriasis common ( 85 % - 90 % ) type . Cutaneous feature individual plaque include circular centrifugal expansion , induration sharp demarcation surround skin , erythema hyperkeratosis . Psoriasis negative impact physical mental aspect life similar major chronic condition . The modality psoriasis treatment divide four main category : topical , phototherapy , systemic drug therapy systemic biological treatment . The currently available treatment psoriasis result either disease suppression disease remission.There many treatment option management psoriasis use topical modality ; however lack respect patient satisfaction durability treatment . Most current topical treatment , many treatment development , base modification steroid structure Vitamin D. Recent research identify broad role histone deacetylase ( HDAC ) proteins numerous signal pathways critical cancer cell survival , epigenetic inheritance , gene regulation , mitosis , signal transduction importantly , inflammation . Theoretically modulation HDAC could lead clinical benefit inflammatory disease .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>1 . Mild moderate chronic plaquetype psoriasis . 2. psoriasis least one year . 3 . Stable disease least two week prior commencement study treatment . 4 . One nominated target lesion must area least 86 x 57 mm2 . 5 . BMI le 35 kg/m2 . 1 . Dermatological Conditions Subjects erythrodermic , guttate , palmar , plantar generalise pustular form psoriasis . Subjects scalp , palmar plantar psoriasis . Subjects skin condition psoriasis , particular eczema , cutaneous infection , significant sun damage inherit skin disorder ( psoriasis ) . 2 . Concurrent Medical Conditions History clinically significant intercurrent disease type ( psoriasis ) . A history moderate severe asthma last 10 year . Major chronic inflammatory disease . Congenital immunodeficiency cancer prone syndrome . History abnormal bleeding tendency thrombophlebitis , history Hepatitis B , Hepatitis C HIV infection . History malignancy ( adequately treat skin carcinoma carcinomainsitu cervix ) . 3 . Laboratory Status Any evidence organ dysfunction , confirm reexamination clinically significant ( i.e . opinion Medical Officer would jeopardise safety subject impact validity study result ) , A creatinine clearance le 75 mL/min . Liver function test &gt; 1.5 x upper limit normal isolated bilirubin . Hepatitis B surface antigen , Hepatitis C antibody , HIV antibodies . 4 . Treatment follow within 4 week prior commencement study treatment duration study : Systemic retinoids . Immunosuppressant agent ( e.g . methotrexate , cyclosporine , azathioprine , thioguanine prednisone , prednisolone , hydroxyurea mycophenolate mofetil ) . Phototherapy photochemotherapy . High potency topical corticosteroid . `` Alternative medicine '' treatment psoriasis . Prolonged sun exposure tan bed use , may opinion Investigator , modify disease activity . 5 . Topical treatment 2 target lesion follow within 2 week prior commencement study treatment duration study Moderate potency topical corticosteroid . Vitamin D analogues topical retinoids . Keratolytics , coal tar dithranol . 6 . Concurrent Medications Subjects receive anticipate receive new medicine ( prescription , overthecounter herbal ) , give systemically topically , within 14 day prior start dose . Subjects may enrol stable exist therapy ( least 60 day ) determine Principal Investigator . 7 . Hypersensitivity History allergy and/or hypersensitivity state ingredient formulation topical agent . A known hypersensitivity lignocaine , surgical dressing may use study procedure . 8 . Females lactate , pregnant planning become pregnant . 9 . Drug Alcohol Abuse History , current evidence , abuse alcohol drug substance , licit illicit , positive urine drug alcohol screen drug abuse alcohol . 10 . Psychiatric Disorder History psychiatric illness may impair ability provide write informed consent 11 . Participation research study within 30 day start dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>psoriasis</keyword>
</DOC>